KangPu's CBL-514 Injectable for Subcutaneous Fat Reduction Approved for Phase 2 Trial by Taiwan TFDA
KangPu has received approval from the Taiwan TFDA for its Phase 2 clinical trial (CBL-0206) for CBL-514, an injectable for abdominal subcutaneous fat reduction, to be conducted in Taiwan and Australia with approximately 250 subjects.
📋 Article Processing Timeline
- 📰 Published: May 19, 2026 at 09:00
- 🔍 Collected: May 20, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 20, 2026 at 08:26 (26 min after Collected)
1. Date of occurrence: May 19, 2026
2. Drug name/code: CBL-514
3. Indication:
- Reduction of subcutaneous fat
- Improvement of moderate to severe cellulite
- Treatment of rare Dercum's disease
4. Development stages:
- Phase 1: Completed.
- Phase 2: CBL-0205 completed; CBL-0206 approved by HREC (Australia) and TFDA (Taiwan).
- Phase 3: CBL-0301 approved in US/Canada; CBL-0302 approved in US.
- NDA: Not yet initiated.
5. Current status:
KangPu will conduct the Phase 2 clinical trial CBL-0206 for CBL-514 in Taiwan and Australia to gather safety and efficacy data for Asian populations to support future NDA filings. Taiwan TFDA approval was granted on May 19, 2026. The trial, enrolling approximately 250 subjects, uses MRI to measure changes in abdominal fat volume and the Abdominal Fat Rating Scale (AFRS) for efficacy assessment.
- Trial design: Phase 2, randomized, placebo-controlled with a long-term re-treatment design.
6. Next steps: Initiating the CBL-0301 clinical trial.
7. Market status: Over 80% of fat reduction procedures are still surgical, which carry significant side effect risks. Non-surgical alternatives are growing but often suffer from poor efficacy or safety concerns (e.g., nerve damage, PAH). ASPS reports indicate over 60% of people avoid existing treatments due to dissatisfaction or fear of side effects.
2. Drug name/code: CBL-514
3. Indication:
- Reduction of subcutaneous fat
- Improvement of moderate to severe cellulite
- Treatment of rare Dercum's disease
4. Development stages:
- Phase 1: Completed.
- Phase 2: CBL-0205 completed; CBL-0206 approved by HREC (Australia) and TFDA (Taiwan).
- Phase 3: CBL-0301 approved in US/Canada; CBL-0302 approved in US.
- NDA: Not yet initiated.
5. Current status:
KangPu will conduct the Phase 2 clinical trial CBL-0206 for CBL-514 in Taiwan and Australia to gather safety and efficacy data for Asian populations to support future NDA filings. Taiwan TFDA approval was granted on May 19, 2026. The trial, enrolling approximately 250 subjects, uses MRI to measure changes in abdominal fat volume and the Abdominal Fat Rating Scale (AFRS) for efficacy assessment.
- Trial design: Phase 2, randomized, placebo-controlled with a long-term re-treatment design.
6. Next steps: Initiating the CBL-0301 clinical trial.
7. Market status: Over 80% of fat reduction procedures are still surgical, which carry significant side effect risks. Non-surgical alternatives are growing but often suffer from poor efficacy or safety concerns (e.g., nerve damage, PAH). ASPS reports indicate over 60% of people avoid existing treatments due to dissatisfaction or fear of side effects.
FAQ
What benefits can CBL-514 offer?
It aims to reduce abdominal subcutaneous fat, improve cellulite, and treat certain rare diseases.
Where are the clinical trials taking place?
This Phase 2 trial (CBL-0206) is being conducted in Taiwan and Australia.
Why is the Taiwan approval significant?
It allows the company to collect safety and efficacy data from Asian populations, supporting future market expansion.